Trial for treating women during the dysfunctional uterine bleeding in child-bearing period and perimenopausal period with Ethinylestradiol and Cyproterone Acetate

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11002030

Enrollment

Unknown

Registered

2011-12-19

Start date

2012-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dysfunctional uterine bleeding

Interventions

Group of Ethinylestradiol and Cyproterone Acetate:tablet 1, q8h, 7days later tablet 1, q12h, 7days later tablet 1, qd, 7days withdrawal, and then with Ethinylestradiol and Cyproterone Acetate tablet 1

Group of MPA:tablet 6, q8h, 7days later tablet 6, q12h, 7days later tablet 6, qd, 7days withdrawal, and then with MPA tablet 6, qd, 14days, for 3 months.

Eligibility

Sex/Gender

Female

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Twenty-fifty; With informed consent form; Accord with diagnosis of dysfunctional uterine bleeding: menstruation lengthens>7 day, and/or menstrual blood>80ml, and/or menstrual cycle<21day.

Exclusion criteria

Exclusion criteria: 1. Gestation related disease; 2. Genital disease such as: uterine sub mucous myoma, endometrial polyp, genital tumor; 3. Genital inflammation; 4. Systemic disease such as: blood disease, liver and kidney crocks up, thyroid gland disease, etc.

Design outcomes

Primary

Measure	Time frame
weight;height;blood loss;time of homeostasis;hemoglobin;platelets;bleeding time and coagulation,;Endometrial pathological examination;	—

Countries

China

Contacts

Public ContactLiu Jiayin

jie.wuyale@gmail.com+86 025 86214093

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026